Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults

Phase 2

Recruiting

• Conditions: Migraine
• Interventions: Drug: Placebo; Drug: MTX101

• Registration Number: NCT06728553
• Lead Sponsor: Manistee Therapeutics

Brief Summary

The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101. The main questions it aims to answer are:

Does the drug MTX101 lower headache pain for participants and the need to use a rescue medication? What side effects, if any, do participants have when taking the drug MTX101? Researchers will compare the drug MTX101 to a placebo (a look-alike substance that contains no drug) to see if the drug MTX101 works to treat acute migraine attacks.

Participants will:

Take the drug MTX101 or a placebo to treat 1 migraine attack with each treatment.

Visit the clinic twice and have one phone call over a 4 week period for checkups and tests.

Keep a diary of their symptoms and the number of times they use a rescue medication.

Detailed Description

Subjects enrolled in the study will be randomized to receive investigational product (MTX101 2mg or placebo), to be taken as soon as they have a migraine headache that reaches moderate to severe intensity. Subjects will take a single dose of either active or placebo to treat one migraine headache. Rescue medication should not be taken until at least 2 hours post study medication dose.

The subject will have a telephone check up within 72 to 120 hours after treatment of the first migraine headache.

The subject will treat a 2nd moderate to severe migraine at least 48 hours after the first treated migraine headache.

The subject will return to the clinic for re-evaluation within a 4 week period from the start of the study.

Study Timeline

• Study First Submitted: 2024-12-06
• Study First Submitted QC: 2024-12-06
• Study First Posted: 2024-12-11
• Study Start: 2025-02-24
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-26
• Last Update Posted: 2025-04-01
• Primary Completion: 2025-06
• Study Completion: 2025-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

1. Male or female aged 18 to 65 years at the time of consent.
2. Onset of migraine headache before age 50.
3. History of episodic migraine headache starting at least 1-year ago with or without aura.
4. Has a minimum of 4 monthly migraine days and not more than 10 migraine days per month.
5. Able to distinguish pain related to migraine attacks from tension-type and cluster headache attacks.
6. Able to understand and provide signed informed consent.
7. Willing and able to comply with all scheduled visits, treatment plan, and other study procedures.

Key

Exclusion Criteria

1. No more than a total of 15 headache days per month.
2. Use of more than 2 migraine preventive medications.
3. Current diagnosis of glaucoma.
4. Use of opioids or barbiturates more than 4 days/month, triptans or ergots 10 or more days/month, or simple analgesics (e.g., aspirin, NSAIDs, acetaminophen) 15 or more days/month in the 3 months prior to Visit 1.
5. Current diagnosis of any post-traumatic headaches, medication overuse headaches, new daily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache), painful cranial neuropathy or daily headaches.
6. Vaccination within less than 7 days from the Screening or plans to get a vaccine during the study or within a week after final study dose.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Subjects will be given one sublingual tablet of matching placebo and instructed to take the tablet after the onset of a migraine of moderate to severe intensity.
Active	MTX101	Subjects will be given one 2 mg sublingual tablet of the investigational product (MTX101) and instructed to take the tablet after onset of a migraine of moderate to severe intensity.

Primary Outcome Measures

Name	Time	Method
Safety assessment (occurrence of adverse events, treatment emergent adverse events and serious adverse events).	Treatment emergent adverse event safety assessments will be limited to the first 48 hours after a treated attack.	To assess the tolerability and safety of MTX101. This objective will be measured by assessing the number of unique subjects with deaths, serious adverse events, and moderate and severe adverse events.

Secondary Outcome Measures

Name	Time	Method
The change in migraine headache pain score, using an 11-point Numerical Rating Scale, (0=no pain, 10=worst possible pain).	From the time of dosing (t=0 hour) to 2 hours post-dose.	This objective will be measured by change in migraine headache pain score, using an 11-point Numerical Rating Scale, (0=no pain, 10=worst possible pain), from the time of dosing (t=0 hour) to 2 hours post-dose as recorded on the subject's Diary.

Trial Locations

Locations (7)

DelRicht Research; 🇺🇸 New Orleans, Louisiana, United States

Kaizen Brain Center; 🇺🇸 La Jolla, California, United States

Clinical Research Institute, LLC; 🇺🇸 Santa Monica, California, United States

Brainstorm Research; 🇺🇸 Miami, Florida, United States

Synergy Clinical Research/Emerald Coast Center for Neurological Disorders; 🇺🇸 Pensacola, Florida, United States

QUEST Research Institute; 🇺🇸 Farmington Hills, Michigan, United States

Wasatch Clinical Research; 🇺🇸 Salt Lake City, Utah, United States